During the past decade, Lekarna Rezidence Nova Karolina conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Lekarna Rezidence Nova Karolina" are "Ankylosing Spondylitis" (1 trials), "Dermatitis, Atopic" (1 trials) and "Rheumatoid Arthritis" (1 trials). Many other conditions were trialed in "Lekarna Rezidence Nova Karolina" in a lesser frequency.

Most popular intervention types in "Lekarna Rezidence Nova Karolina" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Abrocitinib 100 mg" (1 trials), "Abrocitinib 200 mg" (1 trials), "CP-690,550" (1 trials) and "Methotrexate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Lekarna Rezidence Nova Karolina" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Lekarna Rezidence Nova Karolina". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Lekarna Rezidence Nova Karolina, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Lekarna Rezidence Nova Karolina, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".